undamentalytics Newsletter
Sign in

Inmed Pharmaceuticals Inc. income statement

In fiscal 2025, Inmed Pharmaceuticals Inc. reported revenue of $4.9m, up 7.5% on the year before and net income of −$1.7m, or −$8.36 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 2025LTMDec 2025
Revenue214555
Cost of revenue—13333
Gross profit—11121
Research and development574332
General and administrative476656
Operating income−10−19−8———
Net interest income−0—————
Income before tax—−19−8−8−9−8
Income tax——00——
Net income−10−19−8−8−2−1
Diluted EPS−$126.53−$221.13−$21.67−$20.14−$8.36—
Diluted shares (average)——————
EBITDA−10−18−8———

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ENSC vs INMINM vs OCGNINM vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Inmed Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Inmed Pharmaceuticals Inc.